DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for progressive myoclonic epilepsy type 9 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleProgressive myoclonic epilepsy type 9 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for progressive myoclonic epilepsy type 9 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Piracetam was tested in an open-label study of 11 patients with disabling myoclonus due to progressive myoclonus epilepsy. Treatment began at 3.2 g/day and was increased gradually up to 20 g/day. A statistically significant improvement in a total rating score combining motor impairment, functional disability, and global assessment of disability due to myoclonus was seen at the first, sixth, and twelfth months. The severity of other neurological symptoms — seizure frequency and severity, dysarthria, and gait ataxia — did not improve significantly. Two patients reported drowsiness during the first two weeks. The authors concluded that efficacy increased over the first twelve months and then stabilised.
A 1993 review states that there is no cure for progressive myoclonus epilepsy. It names piracetam and 5-hydroxy-L-tryptophan as two drugs available through clinical-research protocols. A 1971 study of 90 children with myoclonic epilepsy found that 73.3% had other seizure types and 75.6% had mental retardation. In 24 patients there were fixed or progressive neurological abnormalities; in 9 of those the brain dysfunction was progressive. Ataxia or cerebellar dysfunction was observed in 24 patients (26.7%), usually transient or recurring.
A 2024 case report describes a single patient with progressive myoclonic epilepsy type 7, caused by a pathogenic variant in KCNC1, whose myoclonus improved after epileptic seizures. The authors suggest this pattern may be a diagnostic clue for that specific subtype. No other patients or quantitative outcomes are reported.
What is still missing: controlled trials with adequate sample sizes for any specific genetic subtype of progressive myoclonic epilepsy, long-term data on functional outcomes beyond myoclonus rating scores, and any evidence that piracetam or other agents alter the progressive course of the underlying disease rather than temporarily suppressing one symptom.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Neurology · 2001 · 73 citations
Long-term Efficacy and Safety of Piracetam in the Treatment of Progressive Myoclonus Epilepsy
AbstractBACKGROUND: Piracetam has been proven to be effective and well tolerated in the treatment of myoclonus in short-term studies. OBJECTIVE: To assess its long-term clinical efficacy, 11 patients with disabling myoclonus due to progressive myoclonus epilepsy were treated with piracetam in an open-label study. METHODS: Neurologic outcome (at the 1st, 6th, 12th, and 18th month of treatment) was assessed by an adjusted sum score of the following 3 indices: motor impairment, functional disability, and global assessment of disability due to myoclonus. Severity of other neurologic symptoms (seizure frequency and severity, dysarthria, and gait ataxia) also was assessed. Treatment with piracetam was initiated at a dose of 3.2 g/d that was gradually increased until stable benefit was noted (maximal dose in the trial was 20 g/d). Concomitant antiepileptic drugs were maintained at their previous dose. RESULTS: Statistically significant improvement in the total rating score was observed after introduction of piracetam at the 1st, 6th, and 12th month of treatment. Severity of other neurologic symptom scores did not improve significantly. Two patients reported drowsiness during the first 2 weeks of treatment. CONCLUSIONS: Piracetam given as add-on therapy seems to be an effective, sustained, and well-tolerated treatment of myoclonus. In patients with progressive myoclonus epilepsy, the efficacy of the drug increased during the first 12 months of treatment and then stabilized.
Abstract90 cases of myoclonic epilepsy in childhood have been presented. The myoclonus was associated with several EEG patterns e. g. short 3-per-second irregular EEG bursts, longer bursts at the same rhythm or 2-per-second complexes. Other seizures were associated with the myoclons in 73.3% of cases and mental retardation was noted in 75.6% of patients. It is proposed that myoclonic epilepsy is not a homogeneous entity but might be divided into several syndromes. Myoclonic epilepsy with fixed or progressive neurological abnormalities was present in 24 patients. Brain dysfunction was progressive in 9 of these. Ataxia or cerebellar dysfunction was observed in 24 patients (26.7%). This was most often a transient and sometimes recurring phenomenon. Myoclonic epilepsy without permanent neurological anomalies has been further separated into 4 subgroups according to the clinical and EEG pattern. Zusammenfassung In dieser Studie werden 90 Kinder mit myoklonischen Anfällen beschrieben. Die Myoklonien waren von verschiedenen EEG-Mustern begleitet, zum Beispiel kurzen irregulären 3-Sekunden-Spitzwellen, längerdauernde Paroxysmen der gleichen Art oder 2-Sekunden-Spitzwellen. In 73,3% der Fälle wurden auch andere als myoklonische Anfälle beobachtet und 75,6% der Kinder waren in ihrer geistigen Entwicklung retardiert. Die myoklonischen Anfälle des Kindesalters sind keine Krankheitseinheit. In 24 Fällen handelt es sich um eine fortschreitende degenerative Erkrankung, in neun anderen Fällen war der Verlauf progressiv. Ataxien oder cerebelläre Dysfunktionen wurden bei 24 Patienten (26,7%) beobachtet. Diese Störungen waren meistens vorübergehend, gelegentlich rezidivierend. Kindliche myoklonische Anfälle ohne dauerhafte neurologische Anomalien konnten aufgr und der klinischen und EEG-Befunde in vier Untergruppen unterteilt werden. Keyword Epilepsy - myoclonus - electroencephalogram
The Clinical Challenge pf Progressive Myoclonus Epilepsy
AbstractHealth care providers who care for patients with seizure disorders should be able to recognize progressive myoclonus epilepsy. Progressive myoclonus epilepsy is a syndrome confused with myoclonic seizures and other epilepsies. The main symptom is myoclonus, a brief involuntary muscle jerk of varying intensity that can throw a patient against a wall or to the ground. This article describes major types of progressive myoclonus epilepsy, a typical case presentation and two clinical drug trials available for these patients. The focus of clinical drug trials is to identify a drug that controls the myoclonus and improves the quality of life for the affected individual. There is no cure for patients with progressive myoclonus epilepsy. 5-hydroxy-L-tryptophan and piracetam are two drugs available through clinical-research protocols to patients with progressive myoclonus epilepsy.
Myoclonus improvement after seizures in progressive myoclonic epilepsy type 7: a case report
AbstractBACKGROUND: Progressive Myoclonic Epilepsy (PME) is a group of rare diseases that are difficult to differentiate from one another based on phenotypical characteristics. CASE REPORT: We report a case of PME type 7 due to a pathogenic variant in KCNC1 with myoclonus improvement after epileptic seizures. DISCUSSION: Myoclonus improvement after seizures may be a clue to the diagnosis of Progressive Myoclonic Epilepsy type 7.
Revista de Biología Tropical · 2014 · 1 citations · open access
Epilepsia mioclónica progresiva tipo Lafora y los casos diagnosticados en Costa Rica
AbstractSe presenta una revisión bibliográfica de los principales aspectos clínicos, patológicos y genéticos de la epilepsia mioclónica progresiva tipo Lafora. Se hace mención a los casos de esta enfermedad diagnosticados en Costa Rica.<br>Lafora’s progressive myoclonus epilepsy and diagnosed cases in Costa Rica. A review of the main clinical, pathologic and genetic aspects of progressive myoclonus epilepsy Lafora type was undertaken. The diagnosed cases of this disorder in Costa Rica are mentioned. Rev. Biol. Trop. 52(3): 571-584. Epub 2004 Dic 15.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
